Rodrigo M. Burgos
HIV Residency (PGY3) Director, College of Pharmacy
ID Residency (PGY2) Director, University of Illinois at Chicago
HIV Residency (PGY2) Assistant Director, College of Pharmacy
Contact
Office Phone:
Email:
Related Sites:
About
Research Interests:
Infectious diseases, virology, HIV, CMV, COVID-19, immunocompromised, opportunistic infections, pharmacoepidemiology
Teaching and Supervision
Spanish for Pharmacists (PMPR 337), 8/25/2025 – 12/5/2025
Spanish for Pharmacists (PMPR 337), 8/25/2025 – 12/5/2025
PDAT 6: Infectious Diseases (PHAR 506), 1/13/2025 – 5/2/2025
PDAT 6: Infectious Diseases (PHAR 506), 1/13/2025 – 5/2/2025
PDAT 6: Infectious Diseases (PHAR 506), 1/13/2025 – 5/2/2025
PDAT 6: Infectious Diseases (PHAR 506), 1/13/2025 – 5/2/2025
PDAT 6: Infectious Diseases (PHAR 506), 1/13/2025 – 5/2/2025
Spanish for Pharmacists (PMPR 337), 8/26/2024 – 12/6/2024
Spanish for Pharmacists (PMPR 337), 8/26/2024 – 12/6/2024
Selected Grants
CTA: GS-US-621-6290 ARTISTRY-2, Phase 3 Double-Blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/ Lenacapavir Versus Biktarvy� (Bictegravir...), Gilead Sciences., 10/15/2024 - 10/15/2025, Obligated Amount: $10000; Anticipated Amount: $10000
CTA - SGN35-035 - A phase 1, single-blind, dose-escalation study to assess the safety and tolerability of brentuximab vedotin (ADCETRIS�) in subjects with human immunodeficiency virus (HIV), Seagen., 4/6/2022 - 4/7/2030, Obligated Amount: $2420558; Anticipated Amount: $2420558
CTA: A retrospective chart review study of cefiderocol real world outcomes and safety in the treatment of patients with Gram-negative bacterial infections (GNBI) in the US and Europe, Shionogi & Co Ltd., 3/8/2022 - 3/8/2027, Obligated Amount: $26830; Anticipated Amount: $26830
CTA - Observational Cohort Study of Cabenuva Utilization, Outcomes, and Patient Experience in the United States (BEYOND), Research Triangle Institute., 9/30/2021 - 12/31/2024, Obligated Amount: $28904; Anticipated Amount: $28904
COVID19 CTA: CoVPN 3003 A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults..., FHI Development 360 LLC., 8/15/2020 - 8/31/2023, Obligated Amount: $904052; Anticipated Amount: $904052
Advanced Manufacturing Technology (AMT) and Cybersecurity Study, Il Manufacturing Excellence Center., 2/1/2020 - 12/31/2020, Obligated Amount: $99456; Anticipated Amount: $99456
Merck Investigator Initiated Studies Program, Merck & Co., Inc.., 10/2019 - 12/31/2024, Obligated Amount: $125941.25; No Anticipated Amount Set
Merck Investigator Initiated Studies Program, Merck & Co., Inc.., 10/2019 - 12/31/2024, Obligated Amount: $125941.25; No Anticipated Amount Set
Elbasvir/grazoprevir (Zepatier) for HCV Treatment in Patients with Substance Use, Merck & Co., Inc.., 2019 - 2023, Obligated Amount: $125941.25; No Anticipated Amount Set
Selected Publications
Burgos, Rodrigo M, Wang, Yifan, Hou, Jysheng, Danziger, Larry H. (2025). Pharmacokinetic drug evaluation of co-packaged sulbactam for injection and durlobactam for injection for the treatment of Acinetobacter baumannii-calcoaceticus complex in HABP/VABP. Expert Opinion on Drug Metabolism & Toxicology, 21, (10), 1135-1149. doi:10.1080/17425255.2025.2567533.
Kazanji, Noora, Max, Blake, Burgos, Rodrigo M, Pham, Jennifer T, Ford, Catherine E. (2025). Third-Trimester HIV Viremia Treated With Long-Acting Cabotegravir and Rilpivirine: A Case Report. Open Forum Infectious Diseases, 12, (10), ofaf604. doi:10.1093/ofid/ofaf604.
Hou, Jysheng, Burgos, Rodrigo M, Danziger, Larry H. (2025). P-1556. A Retrospective Evaluation of Methenamine Safety and Efficacy in An Older Population at an Academic Medical Center. Open Forum Infectious Diseases, 12, (Supplement_1), ofae631.1723. doi:10.1093/ofid/ofae631.1723.
Drwiega, Emily N, Danziger, Larry H, Burgos, Rodrigo M, Michienzi, Sarah M. (2024). Commonly Reported Mosquito-Borne Viruses in the United States: A Primer for Pharmacists. Journal of Pharmacy Practice, 37, (3), 741-752. doi:10.1177/08971900231167929.
Lora, Alfredo J Mena, Burgos, Rodrigo, Huber, Dylan, Sanchez, Lawrence, Ali, Mirza, Krill, Candice, Takhsh, Eden, Bleasdale, Susan C. (2024). Levees for a hundred-year flood: impact of a syndrome-based antimicrobial stewardship intervention for coronavirus disease 2019 on antimicrobial use and resistance. Antimicrobial Stewardship & Healthcare Epidemiology, 4, (1), e131. doi:10.1017/ash.2024.383.
Lora, Alfredo J Mena, Burgos, Rodrigo, Hunt, Aaron E, Wang, Yifan, Huber, Dylan, Sanchez, Lawrence, Ali, Mirza, Krill, Candice, Takhsh, Eden, Bleasdale, Susan C. (2024). Impact of a syndrome-based stewardship intervention on antipseudomonal beta-lactam use, antimicrobial resistance, C. difficile rates, and cost in a safety-net community hospital. Antimicrobial Stewardship & Healthcare Epidemiology, 4, (1), e31. doi:10.1017/ash.2024.28.
Herald, Fischer, Burgos, Rodrigo M. (2023). Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date. Infection and Drug Resistance, 16, 555-568. doi:10.2147/idr.s187360.
Wang, Yifan, Drweiga, Emily N, Danziger, Larry H, Burgos, Rodrigo M. (2023). 2450. Clinical Outcomes of Candida auris Infections at an Academic Medical Center. Open Forum Infectious Diseases, 10, (Supplement_2), ofad500.2068. doi:10.1093/ofid/ofad500.2068.
Lora, Alfredo J Mena, Echeverria, Stephanie L, Lindsey, Brenna, Li, Ella, Sanchez, Lawrence, Truesdell, Tiffany, Takhsh, Eden, Lavani, Romeen, Burgos, Rodrigo. (2023). Feasibility and impact of a monoclonal antibody infusion program in reaching vulnerable underserved communities. Infection Control and Hospital Epidemiology, 44, (10), 1690-1692. doi:10.1017/ice.2023.25.
Professional Leadership
Panel Member, Pharmacology Group, NIH-CDC-HIVMA/IDSA, 7/24/2024 - Present
Panel Member, Section Review Group, NIH-CDC-HIVMA/IDSA, 5/10/2021 - Present
SIDP Taskforce of Diversity, Equity and Inclusion, Society of Infectious Diseases Pharmacists, 1/1/2020 - Present
SIDP Fundraising Committee, 12/20/2019 - Present
Education
Degrees:
Doctor of Pharmacy (Pharm.D.), University of Illinois at Chicago, United States, 2005
Master of Public Health (MPH), University of Illinois at Chicago, United States
Postgraduate Training:
HIV/Infectious Diseases Residency, University of Illinois at Chicago, United States, 2007
Pharmacy Practice Residency, University of Illinois at Chicago, United States, 2006
Chemistry BS Program Completion, University of Illinois at Chicago, United States, 2001
Pre-Pharmacy Program, Truman College, United States, 2000
Chemistry and Pharmacy Program, University of Honduras at Tegucigalpa, Honduras, 1998
Licensures and Certifications
Pharmacist, American Academy of HIV Medicine HIV Pharmacist, 2015 - Present
HIV Expert, American Academy of HIV Medicine HIV Expert, 2008 - Present